Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.10 +0.37 (+2.09%)
Official Closing Price Updated: 7:00 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
From Centogene NV
Via GlobeNewswire
News headline image
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Chief Financial Officer Succession
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Named Global Top Employer for Seventh Consecutive Year
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Time to buy these 3 healthcare companies that raised revenue guidance?
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. 
Via MarketBeat
News headline image
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.